Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00846482 · ClinicalTrials.gov registry record · NA
Exploratory Study Of The ERCC-1 Gene
A NA study, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT00846482 is a NA study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 64 participants.
The verdict
NCT00846482, a NA study, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
This study is for patients with advanced or stage II and III colon or rectal cancer. The primary purpose of this research study is to determine if a particular protein in the patient's blood will change when they receive treatment with a drug called oxaliplatin, which is used to treat the colon or rectal cancer. This protein is called ERCC-1. It is thought that the amount of this protein in the blood could influence the manner in which the patient responds to oxaliplatin.
Interventions
- DRUG Oxaliplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2008-02 |
| Est. Completion | 2018-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00846482
The ClinicalTrials.gov registry entry for NCT00846482 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxaliplatin is the first listed.
NCT00846482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00846482 about?
NCT00846482 is a clinical study titled "Exploratory Study Of The ERCC-1 Gene". This study is for patients with advanced or stage II and III colon or rectal cancer. The primary purpose of this research study is to determine if a particular protein in the patient's blood will change when they receive treatment with a drug called oxaliplatin, which is used to treat the colon or r...
What is the current status of trial NCT00846482?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2008-02. Estimated completion is 2018-12.
What interventions are being tested in trial NCT00846482?
The interventions under investigation include: Oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT00846482?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.